Abstract
This study introduces a novel in vitro adenovirus-based model of persistent TGFβ1 signaling in normal human lung fibroblasts to mimic chronic fibrosis. Using this model, we show that the next-generation REV-ERBα agonist STL1267 robustly inhibits myofibroblast differentiation and ECM gene expression. STL1267 outperforms Food and Drug Administration-approved antifibrotic drugs and modulates immune and circadian signaling pathways, supporting its potential as a promising circadian-based therapeutic strategy for pulmonary fibrosis.
Funding Information
  • National Heart, Lung, and Blood Institute (R01 HL142543)
  • National Institute on Aging (AG060769)
  • National Institute of General Medical Sciences (P20 GM103418)
  • University of Kansas Medical Center (Lied Pre-Clinical Grant)
  • School of Medicine, University of Kansas (Internal Medicine Start-Up Funds)
  • National Center for Advancing Translational Sciences (UL1TR002366 (BERD Voucher))

This publication has 50 references indexed in Scilit: